Ask AI
ProCE Banner Activity

Evolving Role of TROP-2–Directed ADCs as First-line Therapy in TNBC

Slideset

Review key slides on recent advances in the treatment of metastatic triple-negative breast cancer (mTNBC), with a focus on the evolving role of sacituzumab govitecan and datopotamab deruxtecan as TROP-2–directed antibody–drug conjugates (ADCs) in the first-line setting. Learners will examine the clinical evidence supporting newly approved therapies, compare key phase III trial designs and efficacy and safety data, and explore practical considerations for treatment selection, supportive care planning, and integration of these agents into contemporary treatment algorithms. The activity also highlights emerging ADCs, targeted therapies, and combination strategies that may further expand treatment options for patients with mTNBC.

Released: August 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals involved in the management of patients with triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment plans that incorporate TROP-2-directed ADCs for patients with mTNBC aligned with the latest evidence and guideline recommendations for TNBC

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.